Enavogliflozin
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
Product Specifications
CAS Number
[1415472-28-4]
Product Name Alternative
DWP-16001
UNSPSC
12352005
Target
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/enavogliflozin.html
Purity
98.43
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@H]([C@H]1O)[C@@H](O[C@H](CO)[C@H]1O)C2=C(CCO3)C3=C(Cl)C(CC4=CC=C(C5CC5)C=C4)=C2
Molecular Formula
C24H27ClO6
Molecular Weight
446.92
References & Citations
[1]Daewoong speeds up developing antidiabetic Enavogliflozin|[2]These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin|[3]Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong's Enavogliflozin & Janssen Biotech's Golimumab Among Others - ResearchAndMarkets.com
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 4
Isoform
SGLT2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
037687-APC 200 µL
LASS6, CT (CERS6, LASS6, Ceramide synthase 6, LAG1 longevity assurance homolog 6) (APC) discontinued
Ask
View Details